Pilaralisib (BioDeep_00000182430)

   

human metabolite blood metabolite


代谢物信息卡片


2-amino-N-[3-({3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-2-methylpropanamide

化学式: C25H25ClN6O4S (540.1346)
中文名称: Pilaralisib
谱图信息: 最多检出来源 Homo sapiens(blood) 82.93%

分子结构信息

SMILES: CC(C)(C(=O)NC1=CC(=CC=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=C(C=CC(=C4)OC)Cl)N
InChI: InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)

描述信息

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

同义名列表

5 个代谢物同义名

2-amino-N-[3-({3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-2-methylpropanamide; SAR-245408XL-147pilaralisib; Pilaralisib (XL147); Pilaralisib; SAR245408



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Gerald Edelman, Jordi Rodon, Joanne Lager, Christelle Castell, Jason Jiang, Eliezer M Van Allen, Nikhil Wagle, Neal I Lindeman, Lynette M Sholl, Geoffrey I Shapiro. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. The oncologist. 2018 04; 23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. [PMID: 29593099]
  • Marco Falasca, Justin R Hamilton, Maria Selvadurai, Krithika Sundaram, Aleksandra Adamska, Philip E Thompson. Class II Phosphoinositide 3-Kinases as Novel Drug Targets. Journal of medicinal chemistry. 2017 01; 60(1):47-65. doi: 10.1021/acs.jmedchem.6b00963. [PMID: 27644332]
  • Jennifer R Brown, Matthew S Davids, Jordi Rodon, Pau Abrisqueta, Siddha N Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, Farrukh T Awan. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul; 21(14):3160-9. doi: 10.1158/1078-0432.ccr-14-3262. [PMID: 25840972]
  • Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, Eunice L Kwak, Jose Baselga, Irene Braña, Shuchi S Pandya, Christian Scheffold, A Douglas Laird, Linh T Nguyen, Yi Xu, Coumaran Egile, Gerald Edelman. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Jan; 20(1):233-45. doi: 10.1158/1078-0432.ccr-13-1777. [PMID: 24166903]